Treatment of vancomycin-intermediate Staphylococcus aureus (VISA) endocarditis with linezolid

International Journal of Infectious Diseases

Volumn 14, Issue SUPPL. 3, 2010, Pages

  Balkhair, Abdullah ^a   Muharrmi, Zakariya Al ^a   Darwish, Laila ^a   Farhan, Hatem ^a   Sallam, Mansour ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

Endocarditis; Linezolid; MRSA; Staphylococcus aureus; VISA

Indexed keywords

FUSIDIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; LINEZOLID;

ADULT; ANAMNESIS; ARTICLE; BACTERIAL ENDOCARDITIS; CASE REPORT; ECHOCARDIOGRAPHY; FOLLOW UP; HUMAN; MALE; NEUTROPENIA; STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; ECHOCARDIOGRAPHY; ENDOCARDITIS, BACTERIAL; FUSIDIC ACID; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MITRAL VALVE; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 77957363948     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.07.023     Document Type: Article

References (15)

1. Hiramatsu K., Aritaka N., Hanaki H., Kawasaki S., Hosoda Y., Hori S., et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997, 350:1670-1673.
2. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin- resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997, 40:135-136.
3. Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996. MMWR Morb Mortal Wkly Rep 1997, 46:624-626. Centers for Disease Control and Prevention (CDC).
4. Liñares J. The VISA/GISA problem: therapeutic implications. Clin Microbiol Infect 2001, 7(Suppl 4):8-15.
5. Shaikh Z.H., Wallace E.R., Strelczyk K.S. Vancomycin-intermediate Staphylococcus aureus (VISA) scare: an opportunity to put infection control (IC) processes to the test. Am J Infect Control 2007, 35:E105.
6. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S15. Wayne, PA: CLSI; 2005.
7. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. CLSI document M100-S16. Wayne, PA: CLSI; 2006.
8. Cui L., Iwamoto A., Lian J.Q., Neoh H., Maruyama T., Horikawa Y., et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50:428-438.
9. Levine D.P. Vancomycin: a history. Clin Infect Dis 2006, 42:S5-12.
10. Centers for Disease Control and Prevention. Laboratory detection of vancomycin-intermediate/resistant Staphylococcus aureus (VISA/VRSA). Updated: April 2006, Accessed Dec 1st 2009-12-01. http://www.cdc.gov/ncidod/dhqp/ar_visavrsa_labFAQ.html.
11. Weinstein R.A. Vancomycin-intermediate and resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001, 32:108-115.
12. Tenover F.C., Moellering R.C. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007, 44:1208-1215.
13. Bouza E., Munoz P. Linezolid: pharmacokinetic characteristics and clinical studies. Clin Microbiol Infect 2001, 7(Suppl 4):75-82.
14. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 358(9277):207-208.
15. Muñoz P., Rodríguez-Creixéms M., Moreno M., Marín M., Ramallo V., Bouza E. Linezolid therapy for infective endocarditis. Clin Microbiol Infect 2007, 13:211-215. GAME Study Group.